Abstract
Context
Anti-retroviral therapy (ART) dramatically reduced AIDS development, thus enabling patients to live as long as the general population. New challenges have emerged particularly cardiometabolic diseases and weight gain, with some HIV patients seeking bariatric surgery (BS). However, BS outcomes during HIV remain poorly described, with scarce data on ART pharmacokinetic post-BS.
Objective
Describing sleeve gastrectomy (SG) results in HIV patients in terms of ART pharmacokinetic, HIV control, weight loss, and metabolic outcomes.
Design, Setting, and Patients
Prospective study of HIV patients undergoing SG in a referral academic center, with at least 6 months follow-up.
Main Outcome Measure
Clinical and biological parameters, HIV medical history, and ART pharmacokinetics were gathered before and post-SG.
Results
Seventeen patients (mean BMI = 44.2 ± 5.7 kg m−2) and major obesity-related diseases (47% type-2 diabetes, 64% obstructive sleep apnea, 70% hypertension) underwent SG during a mean 2 years of follow-up. They displayed an average of 20% reduction of initial BMI and improved body composition, similarly to obese non-HIV patients. SG improved metabolic status. All patients had undetectable viral load before BS. Upon HIV follow-up, 12 patients had undetectable viral load with correct ART kinetic parameters (3 and 6 months); 4 displayed detectable viral load along with significant decrease in raltegravir and atazanavir treatment exposure, leading to ART change with subsequent undetectable viral load; and 1 had persistent detectable viral load despite ART change.
Conclusions
SG seems effective and safe in obese HIV patients. However, ART treatment should be monitored post-SG to control HIV infection. We suggest that some ART should be adapted before SG conjoints with infectious disease specialists.
Similar content being viewed by others
References
Antiretroviral Therapy Cohort Collaboration. Life expectancy of individuals on combination antiretroviral therapy in high-income countries: a collaborative analysis of 14 cohort studies. Lancet Lond Engl. 2008;372:293–9.
Lakey W, Yang L-Y, Yancy W, et al. Short communication: from wasting to obesity: initial antiretroviral therapy and weight gain in HIV-infected persons. AIDS Res Hum Retrovir. 2013;29:435–40.
Crum-Cianflone N, Roediger MP, Eberly L, et al. Increasing rates of obesity among HIV-infected persons during the HIV epidemic. PLoS One. 2010;5:e10106.
Nsagha DS, Assob JCN, Njunda AL, et al. Risk factors of cardiovascular diseases in HIV/AIDS patients on HAART. Open AIDS J. 2015;9:51–9.
Pourcher G, Costagliola D, Martinez V. Obesity in HIV-infected patients in France: prevalence and surgical treatment options. J Visc Surg. 2015;152:33–7.
Angrisani L, Santonicola A, Iovino P, et al. Bariatric surgery and endoluminal procedures: IFSO worldwide survey 2014. Obes Surg. 2017;27:2279–89.
Sjöström L, Peltonen M, Jacobson P, et al. Bariatric surgery and long-term cardiovascular events. JAMA J Am Med Assoc. 2012;307:56–65.
Sjöström L, Narbro K, Sjöström CD, et al. Effects of bariatric surgery on mortality in Swedish obese subjects. N Engl J Med. 2007;357:741–52.
Buse JB, Caprio S, Cefalu WT, et al. How do we define cure of diabetes? Diabetes Care. 2009;32:2133–5.
Aron-Wisnewsky J, Sokolovska N, Liu Y, et al. The advanced-DiaRem score improves prediction of diabetes remission 1 year post-roux-en-Y gastric bypass. Diabetologia. 2017;60:1892–902.
Reges O, Greenland P, Dicker D, et al. Association of Bariatric Surgery Using Laparoscopic Banding, roux-en-Y gastric bypass, or laparoscopic sleeve gastrectomy vs usual care obesity management with all-cause mortality. JAMA. 2018;319:279–90.
Zellmer JD, Mathiason MA, Kallies KJ, et al. Is laparoscopic sleeve gastrectomy a lower risk bariatric procedure compared with laparoscopic Roux-en-Y gastric bypass? A meta-analysis. Am J Surg. 2014;208:903–10. discussion 909-910
Pourcher G, Peytavin G, Schneider L, et al. Bariatric surgery in HIV patients: experience of an obesity reference center in France. Surg Obes Relat Dis Off J Am Soc Bariatr Surg. 2017;13:1990–6.
Sharma G, Strong AT, Boules M, Tu C, Szomstein S, Rosenthal R, et al. Comparative outcomes of bariatric surgery in patients with and without human immunodeficiency virus. Obes Surg 2017;28:1070–79.
Alfa-Wali M, Seechurn S, Ayodeji O, et al. Outcomes of bariatric surgery in human immunodeficiency virus positive individuals: a single center experience. Minerva Chir. 2016;71:233–8.
Muzard L, Alvarez J-C, Gbedo C, et al. Tenofovir pharmacokinetic after sleeve-gastrectomy in four severely obese patients living with HIV. Obes Res Clin Pract. 2017;11:108–13.
Selke H, Norris S, Osterholzer D, et al. Bariatric surgery outcomes in HIV-infected subjects: a case series. AIDS Patient Care STDs. 2010;24:545–50.
Zivich S, Cauterucci M, Allen S, et al. Long-term virologic outcomes following bariatric surgery in patients with HIV. Obes Res Clin Pract. 2015;9:633–5.
Panko N, Dunford G, Lutfi R. HIV infection is not a contraindication to laparoscopic sleeve gastrectomy for morbid obesity. Obes Surg. 2018;28:464–8.
Fysekidis M, Cohen R, Bekheit M, et al. Sleeve gastrectomy is a safe and efficient procedure in HIV patients with morbid obesity: a case series with results in weight loss, comorbidity evolution, CD4 count, and viral load. Obes Surg. 2015;25:229–33.
Flancbaum L, Drake V, Colarusso T, et al. Initial experience with bariatric surgery in asymptomatic human immunodeficiency virus-infected patients. Surg Obes Relat Dis Off J Am Soc Bariatr Surg. 2005;1:73–6.
Eddy F, Elvin S, Sanmani L. Bariatric surgery: an HIV-positive patient’s successful journey. Int J STD AIDS 2015;27:70–1.
Fazylov R, Soto E, Merola S. Laparoscopic gastric bypass surgery in human immunodeficiency virus-infected patients. Surg Obes Relat Dis Off J Am Soc Bariatr Surg. 2007;3:637–9.
MacBrayne CE, Blum JD, Kiser JJ. Tenofovir, emtricitabine, and darunavir/ritonavir pharmacokinetics in an HIV-infected patient after Roux-en-Y gastric bypass surgery. Ann Pharmacother. 2014;48:816–9.
Malone M. Altered drug disposition in obesity and after bariatric surgery. Nutr Clin Pract Off Publ Am Soc Parenter Enter Nutr. 2003;18:131–5.
Edwards A, Ensom MHH. Pharmacokinetic effects of bariatric surgery. Ann Pharmacother. 2012;46:130–6.
Verger EO, Aron-Wisnewsky J, Dao MC, Kayser BD, Oppert J-M, Bouillot J-L, et al. Micronutrient and protein deficiencies after gastric bypass and sleeve gastrectomy: a 1-year follow-up. Obes Surg 2015;26:785–96.
Yuen GJ, Lou Y, Bumgarner NF, et al. Equivalent steady-state pharmacokinetics of lamivudine in plasma and lamivudine triphosphate within cells following administration of lamivudine at 300 milligrams once daily and 150 milligrams twice daily. Antimicrob Agents Chemother. 2004;48:176–82.
Wang LH, Chittick GE, McDowell JA. Single-dose pharmacokinetics and safety of abacavir (1592U89), zidovudine, and lamivudine administered alone and in combination in adults with human immunodeficiency virus infection. Antimicrob Agents Chemother. 1999;43:1708–15.
Curran A, Martí R, López RM, et al. Darunavir and ritonavir Total and unbound plasmatic concentrations in HIV-HCV-Coinfected patients with hepatic cirrhosis compared to those in HIV-monoinfected patients. Antimicrob Agents Chemother. 2015;59:6782–90.
Blum MR, Chittick GE, Begley JA, et al. Steady-state pharmacokinetics of emtricitabine and tenofovir disoproxil fumarate administered alone and in combination in healthy volunteers. J Clin Pharmacol. 2007;47:751–9.
Zong J, Chittick GE, Wang LH, et al. Pharmacokinetic evaluation of emtricitabine in combination with other nucleoside antivirals in healthy volunteers. J Clin Pharmacol. 2007;47:877–89.
Iwamoto M, Wenning LA, Mistry GC, et al. Atazanavir modestly increases plasma levels of raltegravir in healthy subjects. Clin Infect Dis Off Publ Infect Dis Soc Am. 2008;47:137–40.
von Hentig N, Babacan E, Lennemann T, et al. The steady-state pharmacokinetics of atazanavir/ritonavir in HIV-1-infected adult outpatients is not affected by gender-related co-factors. J Antimicrob Chemother. 2008;62:579–82.
Ofotokun I, Chuck SK, Binongo JN, et al. Lopinavir/ritonavir pharmacokinetic profile: impact of sex and other covariates following a change from twice-daily to once-daily therapy. J Clin Pharmacol. 2007;47:970–7.
Sawaya RA, Jaffe J, Friedenberg L, et al. Vitamin, mineral, and drug absorption following bariatric surgery. Curr Drug Metab. 2012;13:1345–55.
Mans E, Serra-Prat M, Palomera E, et al. Sleeve gastrectomy effects on hunger, satiation, and gastrointestinal hormone and motility responses after a liquid meal test. Am J Clin Nutr. 2015;102:540–7.
Ying VWC, Kim SHH, Khan KJ, et al. Prophylactic PPI help reduce marginal ulcers after gastric bypass surgery: a systematic review and meta-analysis of cohort studies. Surg Endosc. 2015;29:1018–23.
Ogawa R, Echizen H. Drug-drug interaction profiles of proton pump inhibitors. Clin Pharmacokinet. 2010;49:509–33.
Ray JE, Marriott D, Bloch MT, et al. Therapeutic drug monitoring of atazanavir: surveillance of pharmacotherapy in the clinic. Br J Clin Pharmacol. 2005;60:291–9.
Dybul M, Fauci AS, Bartlett JG, et al. Guidelines for using antiretroviral agents among HIV-infected adults and adolescents recommendations of the Panel on Clinical Practices for Treatment of HIV. MMWR Recomm Rep Morb Mortal Wkly Rep Recomm Rep Cent Dis Control. 2002;51:1–55.
Acosta EP, Gerber JG, Adult Pharmacology Committee of the AIDS Clinical Trials Group. Position paper on therapeutic drug monitoring of antiretroviral agents. AIDS Res Hum Retrovir. 2002;18:825–34.
Moss DM, Siccardi M, Murphy M, et al. Divalent metals and pH alter raltegravir disposition in vitro. Antimicrob Agents Chemother. 2012;56(6):3020–6.
Kassir R, Huart E, Tiffet O, et al. Feasibility of bariatric surgery in the HIV-infected patients. Obes Surg. 2017;27:818–9.
Soares LR, da Silva DC, Gonsalez CR, et al. Discordance between body mass index and anthropometric measurements among HIV-1-infected patients on antiretroviral therapy and with lipoatrophy/lipohypertrophy syndrome. Rev Inst Med Trop São Paulo. 2015;57:105–10.
Ciangura C, Bouillot J-L, Lloret-Linares C, et al. Dynamics of change in total and regional body composition after gastric bypass in obese patients. Obes Silver Spring Md. 2010;18:760–5.
Acknowledgements
The authors wish to thank Ms. Valentine Lemoine for her help in data collection and Dr. Florence Marchelli, MD, for her contribution to management of the clinical and biological database.
Financial Support
This study is supported by CRC fibrota (AP-HP).
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Conflict of Interest
The authors declare that they have no conflict of interest.
Ethical Statement
All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and/or national research committee and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards.
Informed Consent
Informed consent was obtained from all individual participants included in the study.
Electronic Supplementary Material
Supplementary Fig. 1
Pharmacokinetic profile for safe ART at baseline and post-BS: Cmin, Cmax, and AUC are represented for each drug at baseline (black) compared with literature optimal concentrations (red) and 3 months post-SG (blue). a Pre- and post-surgery and literature [28] of lamivudine, data expressed in mean ± standard deviation; b pre- and post-surgery and literature [29] of abacavir, data expressed in mean ± standard deviation; c pre- and post-surgery and literature [30] of darunavir, data expressed in mean ± min and max. (GIF 170 kb)
Supplementary Fig. 2
Corpulence evolution in obese HIV patients as compared with non-HIV obese patients: a non-significant difference weight evolution between the two groups at baseline and during the first year of follow-up and b non-significant body composition evolution between the two groups at baseline and during the first year of follow-up (GIF 226 kb)
Rights and permissions
About this article
Cite this article
Amouyal, C., Buyse, M., Lucas-Martini, L. et al. Sleeve Gastrectomy in Morbidly Obese HIV Patients: Focus on Anti-retroviral Treatment Absorption After Surgery. OBES SURG 28, 2886–2893 (2018). https://doi.org/10.1007/s11695-018-3308-7
Published:
Issue Date:
DOI: https://doi.org/10.1007/s11695-018-3308-7